PD-L1 status has long been explored as a predictive biomarker for immune checkpoint inhibitors. However, the clinical evidence for its efficacy has been mixed, so how should PD-L1 status be used in clinical practice? 
In the first episode in this series on immuno-oncology, Dr Vaibhav Patel from the Icahn School of Medicine at Mount Sinai, New York, answers questions about how PD-L1 status can or cannot influence treatment decisions in oncology.
References:
Kulangara K, et al. Arch Pathol Lab Med. 2019; 143(3): 330-337
Mok S, et al. Lancet. 2019; 393(10183): 1819-1830
Pacheco J. Transl Lung Cancer Res. 2019; 8(5): 723-727
Xu Y, et al. Transl Lung Cancer Res. 2019; 8(4): 413-428
Access more free education today! Visit the website, follow us on Twitter (@onckip) or connect on LinkedIn.
This independent educational activity is supported by an educational grant from Merck, Sharpe & Dohme Corp. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; MSD corp. has had no influence on the content of this education.